Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial) The ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Medically reviewed by Douglas A. Nelson, MD The treatment for leukemia depends on many factors, including the type, subtype, and stage of the disease, and a person’s age and general health. Treatment ...

IntroductionBruton’s tyrosine kinase (BTK) is at the core of present day treatment in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) which in turn is redefining first line and ...

Lipsky,MD, highlights 6-year follow-up data from the phase 3 SEQUOIA trial (NCT03336333) showing that the BTK inhibitor ...